BARCELONA, Spain—Two new entries in the treatment of metastatic colorectal cancer were discussed here at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer, each showing promise in a heavily pretreated population.
The placebo-controlled, randomized, Phase III trials were for regorafenib (CONCUR) and TAS-102 (RECOURSE).
“The good news is, both of these drugs are active, said Richard M. Goldberg, MD, Professor and Physician-in-Chief at Ohio State University James Cancer Hospital and Comprehensive Cancer Center, who was the Discussant for both trials. He called the trials “unequivocally positive.”
Goldberg congratulated the researchers for well-designed trials in appropriate populations that showed significant survival and response benefit for each drug. But toxicities for regorafenib were too high, he said, recommending dose reductions or changes in dosing strategy.
No comments:
Post a Comment